The Fly | KYMR

Kymera Therapeutics

· KYMR

Dashboard

Financials

Ratios

Transcripts

Valuation

Today

Kymera Therapeutics completes enrollment in BROADEN2 trial

KYMR

7:15 AM

Yesterday

Kymera Therapeutics appoints Felix Baker as chairman

KYMR

Yesterday, 4:05 PM

Monday

Canaccord sees potential Apogee buyout as 'huge win' for sector

Jun 22, 6:45 AM

Over a week ago

Kymera Therapeutics participates in a conference call with JPMorgan

KYMR

Jun 17, 1:21 PM

Kymera Therapeutics presents preclinical lupus data for KT-579

KYMR

Jun 8, 9:06 AM

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls

+13

May 6, 9:38 AM

Kymera Therapeutics initiated with bullish view at Canaccord, here's why

KYMR

May 6, 6:39 AM

Kymera Therapeutics initiated with bullish view at Canaccord

KYMR

May 6, 5:22 AM

Kymera Therapeutics price target lowered by $4 at Morgan Stanley, here's why

KYMR

Apr 30, 11:56 AM

Kymera Therapeutics reports Q1 EPS (71c), consensus (86c)

KYMR

Apr 30, 7:46 AM

FDA grants fast track designation to Kymera Therapeutics KT-621

KYMR

Apr 13, 7:03 AM

Kymera Therapeutics announces Gilead option exercise to license KT-200

Apr 9, 7:08 AM

Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621

KYMR

Mar 29, 10:26 AM

Kymera Therapeutics assumed with a Buy at Jefferies

KYMR

Mar 16, 9:25 AM

Kymera Therapeutics price target raised by $38 at UBS, here's why

KYMR

Mar 3, 8:34 AM

Kymera Therapeutics price target raised by $5 at Stephens, here's why

KYMR

Mar 2, 7:22 AM

Kymera Therapeutics price target raised by $10 at Citi

KYMR

Mar 2, 6:42 AM

Kymera Therapeutics price target lowered by $4 at Morgan Stanley, here's why

KYMR

Feb 26, 3:30 PM

Kymera Therapeutics price target raised by $15 at Piper Sandler, here's why

KYMR

Feb 26, 8:33 AM

Kymera Therapeutics reports Q4 EPS (97c), consensus (79c)

KYMR

Feb 26, 7:06 AM

Kymera Therapeutics initiates dosing in BREADTH Phase 2b trial of KT-621

KYMR

Jan 29, 7:18 AM

Kymera Therapeutics assumed with an Overweight at Barclays

KYMR

Jan 27, 4:26 PM

Mizuho biotech analysts hold an analyst/industry conference call

Jan 26, 4:55 AM

Pioneering TPD Platform: Kymera's proprietary PLAT.Rx® platform provides a systematic and efficient engine for the discovery and development of novel targeted protein degraders, offering a significant technological edge in the field.

First-in-Class Clinical Pipeline: The company has advanced multiple first-in-class degraders into clinical development, notably KT-333 (STAT3 degrader) and KT-6121 (MEK degrader), addressing previously undruggable or challenging targets with high commercial potential.

Broad Therapeutic Reach: Kymera's pipeline spans multiple high-value therapeutic areas, including oncology and immunology, diversifying its risk and expanding the potential market opportunities for its degrader programs.

Clinical Trial Failure and Delays: Kymera's drug candidates may not demonstrate sufficient efficacy or safety in clinical trials, leading to program termination or significant delays in development.

Regulatory Approval Uncertainty: Even with successful clinical trial data, Kymera's drug candidates may not receive necessary regulatory approvals from health authorities, preventing commercialization.

Intense Market Competition: Kymera faces significant competition from other pharmaceutical and biotechnology companies developing treatments for similar indications, which could impact market share and profitability.

Charts

Clinical Trial Failure and Delays: Kymera's drug candidates may not demonstrate sufficient efficacy or safety in clinical trials, leading to program termination or significant delays in development.